Project Details
Description
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
| Status | Finished |
|---|---|
| Effective start/end date | 2/21/25 → 11/30/25 |
Funding
- EYEPOINT PHARMACEUTICALS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.